marketcaparena
Search

    COAG

    Hemab Therapeutics Holdings, Inc.

    Company overview

    Market capitalization
    $1.55B
    Employees
    59
    Latest publication
    2026-09-29
    About Hemab Therapeutics Holdings, Inc.

    Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ1 20252025-03-31 · USD
    Total Revenue0USD0USD
    Research Development19,461,000USD14,101,000USD
    Selling General Administrative4,151,000USD2,459,000USD
    Total Operating Expenses23,612,000USD16,560,000USD
    Operating Income-23,612,000USD-16,560,000USD
    Interest Income1,219,000USD473,000USD
    Net Interest Income1,219,000USD473,000USD
    Income Before Tax-22,675,000USD-15,496,000USD
    Tax Provision12,000USD-190,000USD
    Net Income-22,687,000USD-15,306,000USD
    Net Income From Continuing Ops-22,687,000USD-15,306,000USD
    Reconciled Depreciation73,000USD75,000USD
    Total Other Income Expense Net-282,000USD591,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USD
    Total Revenue0USD0USD
    Research Development59,632,000USD41,412,000USD
    Selling General Administrative10,487,000USD8,971,000USD
    Total Operating Expenses70,119,000USD50,383,000USD
    Operating Income-70,119,000USD-50,383,000USD
    Interest Income1,974,000USD3,740,000USD
    Net Interest Income1,974,000USD3,740,000USD
    Income Before Tax-64,140,000USD-48,522,000USD
    Tax Provision-227,000USD185,000USD
    Net Income-63,913,000USD-48,707,000USD
    Net Income From Continuing Ops-63,913,000USD-48,707,000USD
    Reconciled Depreciation304,000USD248,000USD
    Total Other Income Expense Net4,005,000USD-1,879,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USD
    Total Assets467,781,000USD175,258,000USD
    Cash And Equivalents237,366,000USD—
    Cash And Short Term Investments457,460,000USD—
    Short Term Investments220,094,000USD113,671,000USD
    Total Current Assets463,998,000USD169,431,000USD
    Other Current Assets6,538,000USD—
    Other Non Current Assets2,286,000USD—
    Total Liabilities13,510,000USD—
    Total Current Liabilities12,944,000USD13,189,000USD
    Other Current Liabilities990,000USD—
    Total Stockholder Equity454,271,000USD-198,618,000USD
    Total Equity Including Noncontrolling Interest-454,271,000USD—
    Property Plant Equipment Net1,497,000USD1,587,000USD
    Accounts Payable6,232,000USD5,682,000USD
    Short Term Debt460,000USD—
    Retained Earnings-228,695,000USD-204,545,000USD
    Accumulated Other Comprehensive Income-2,748,000USD—
    Total Liab—373,876,000USD
    Capital Stock—0USD
    Cash—49,860,000USD
    Property Plant Equipment Gross—2,383,000USD
    Common Stock Shares Outstanding—44,192,910shares
    Non Current Assets Total—5,827,000USD
    Non Current Liabilities Total—360,687,000USD
    Non Currrent Assets Other—4,240,000USD
    Net Working Capital—156,242,000USD
    Unclassified Current Assets—5,900,000USD
    Unclassified Current Liabilities—7,507,000USD
    Unclassified Non Current Liabilities—360,687,000USD
    Unclassified Equity—5,927,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USD
    Total Assets194,783,000USD96,278,000USD
    Total Liab371,418,000USD211,551,000USD
    Total Stockholder Equity-176,635,000USD-115,273,000USD
    Capital Stock132,000USD132,000USD
    Retained Earnings-181,858,000USD-117,945,000USD
    Cash87,974,000USD74,407,000USD
    Total Current Assets192,551,000USD93,235,000USD
    Total Current Liabilities10,677,000USD6,685,000USD
    Short Term Investments97,511,000USD13,918,000USD
    Accounts Payable5,734,000USD3,157,000USD
    Property Plant Equipment Net1,701,000USD2,567,000USD
    Property Plant Equipment Gross2,424,000USD2,986,000USD
    Common Stock Shares Outstanding44,192,910shares44,192,910shares
    Non Current Assets Total2,232,000USD3,043,000USD
    Non Current Liabilities Total360,741,000USD204,866,000USD
    Non Currrent Assets Other531,000USD476,000USD
    Net Working Capital181,874,000USD86,550,000USD
    Unclassified Current Assets7,066,000USD4,910,000USD
    Unclassified Current Liabilities4,943,000USD3,528,000USD
    Unclassified Non Current Liabilities360,741,000USD204,803,000USD
    Unclassified Equity5,091,000USD2,540,000USD
    Non Current Liabilities Other—63,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ1 20252025-03-31 · USD
    Net Income-22,687,000USD-15,306,000USD
    Depreciation73,000USD75,000USD
    Stock Based Compensation1,318,000USD459,000USD
    Other Non Cash Items153,000USD521,000USD
    Change In Working Capital375,000USD1,426,000USD
    Total Cash From Operating Activities-21,584,000USD-13,033,000USD
    Capital Expenditures-112,000USD-16,000USD
    Free Cash Flow-21,696,000USD-13,049,000USD
    Investments-15,735,000USD-5,978,000USD
    Net Borrowings-46,000USD-29,000USD
    Total Cash From Financing Activities-460,000USD-29,000USD
    Change In Cash-38,114,000USD-19,056,000USD
    Begin Period Cash Flow87,974,000USD74,407,000USD
    End Period Cash Flow49,860,000USD55,351,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USD
    Net Income-63,913,000USD-48,707,000USD
    Depreciation304,000USD248,000USD
    Stock Based Compensation2,011,000USD1,906,000USD
    Other Non Cash Items-464,000USD794,000USD
    Change In Working Capital1,355,000USD1,447,000USD
    Total Cash From Operating Activities-61,475,000USD-45,592,000USD
    Capital Expenditures-16,000USD-282,000USD
    Free Cash Flow-61,491,000USD-45,874,000USD
    Investments-81,466,000USD62,185,000USD
    Net Borrowings-120,000USD-100,000USD
    Total Cash From Financing Activities156,301,000USD-100,000USD
    Issuance Of Capital Stock156,421,000USD0USD
    Change In Cash13,567,000USD16,211,000USD
    Begin Period Cash Flow74,407,000USD58,196,000USD
    End Period Cash Flow87,974,000USD74,407,000USD
    Unclassified Operating Cash Flow—-1,280,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    No revenue breakdown is currently published for this company.

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.